Orellanine

DB19263InvestigationalSmall molecule

Orellanine is under investigation in clinical trial NCT05287945 (Study of Orellanine in Metastatic Clear-cell or Papillary Renal Cell Carcinoma).

Chemical structure of Orellanine
Mechanism
Curator reviewed
Formula / weight
C10H8N2O6 · 252.182 g/mol (avg)
Also known as
(2,2'-bipyridine)-3,3',4,4'-tetrol, 1,1'-dioxide · 3,3',4,4'-tetrahydroxy-2,2'-bipyridine-1,1'-dioxide

Resolves to

Compound
UNII082U1GSX3DCAS37338-80-0ChEMBLCHEMBL2152646
Structure
InChIKeyJEWWXPOUSBVQKG-UHFFFAOYSA-NSMILESOC1=CC=[N+]([O-])C(=C1O)C1=C(O)C(O)=CC=[N+]1[O-]

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Orellanine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In